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A 61-year-old man with locally advanced (T3 N1 M0)esophageal adenocarcinoma involving the distal esophagus
and gastric cardia was initially treated with four cycles of
epirubicin, oxaliplatin, and capecitabine and three cycles of
docetaxel and irinotecan. He was then treated with concurrent
chemoradiation consisting of 5-fluorouracil, docetaxel, and 50.4
Gy of intensity-modulated radiation therapy to the primary
malignancy and locoregional nodes. A positron-emission to-
mography/computed tomography (PET/CT) scan with fluorode-
oxyglucose (FDG) performed 5 weeks after completion of radi-
ation therapy showed a decrease in the size and intensity of the
primary neoplasm in the distal esophagus and resolution of
tracer uptake in locoregional paraesophageal and left gastric
lymph node metastases that were present on a pretreatment
PET/CT scan. However, there was a new ill-defined nodular
area of hypermetabolism (SUVmax  7.0) in the left lobe of the
liver, measuring approximately 3.5 cm in diameter (Figures 1
and 2). Contrast-enhanced CT of the abdomen showed that the
increased FDG uptake corresponded to a poorly marginated
region of mixed attenuation and heterogeneous enhancement in
the lateral segment of the left lobe of the liver (Figure 3).
CT-guided liver biopsy of this region was performed,
with fine needle aspiration cytology that showed reactive
hepatocytes but no malignant cells. Review of the radiation
dosimetric intensity-modulated radiation therapy treatment
curves showed that the FDG-avid hepatic lesion corre-
sponded to an area of radiation dose of 40 to 45 Gy (Figure
4). Because the liver is susceptible to radiation injury at a
dose above 30 Gy, the abnormality was presumed to be due
to radiation-induced injury. An intraoperative liver wedge
biopsy obtained immediately before planned Ivor-Lewis
esophagectomy confirmed the absence of metastatic disease
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FIGURE 1. Initial staging coronal whole body positron-emis-
sion tomography (PET) showed the primary tumor in the distal
esophagus (SUVmax of 6.6) and adjacent left gastric lymph
nodes (SUVmax of 4.4). There were no liver metastases. SUV,
standard uptake value.
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and showed marked sinusoidal dilatation and congestion,
mild portal fibrosis, and mild chronic inflammation consistent
with radiation-induced hepatic injury. The patient proceeded
to have Ivor-Lewis esophagectomy and mediastinal and ab-
dominal lymph node dissection.
DISCUSSION
Multimodality treatment with chemotherapy, radiation,
and surgical resection is increasingly being used in patients with
locally advanced esophageal cancer.1,2 The appropriate selection
of patients who undergo preoperative chemoradiation therapy
(CRT) followed by surgical resection is important as this therapy
is associated with significant morbidity. In this regard, reassess-
ment by CT after CRT often does not correlate with pathologic
response. The functional information provided by FDG-PET/CT
can provide additive information with regard to locoregional
response and aiding in the detection of occult metastases.3,4 One
of the causes of false-positive PET scanning is uptake in the liver
adjacent to a distal esophageal cancer after CRT because of
radiation-induced injury. This new case has PET/CT findings
similar to those reported in a recent series of 26 patients with
esophageal cancer treated with CRT.5 In that series, two patients
(7.5%) developed FDG-avid radiation-induced injury in the left
lobe of the liver 6 weeks after completion of therapy, whereas 15
had attenuation and contrast abnormalities detected on CT.5 The
activity on PET in these cases is most likely due to tracer uptake
in active leukocytes forming the inflammatory response to the
radiation-induced hepatic injury. The imaging appearance of
hepatic radiation injury in patients with esophageal cancer on
PET/CT can vary from focal to diffuse increased FDG uptake
and can be misinterpreted as hepatic metastatic disease.5
In summary, therapeutic doses of radiation to the liver
after CRT can result in metabolic changes in the liver in patients
with distal esophageal cancer. Although often diffuse in nature,
this uptake can be focal and nodular and could be mistaken for
metastatic disease. Awareness of the occurrence of radiation-
induced hepatic injury and knowledge of the typical location and
appearance on PET/CT imaging in patients with distal esopha-
geal malignancy receiving CRT can be useful in suggesting the
diagnosis and in preventing misinterpretation.
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